This article is a continuation of our previously published annual reviews of Based on these studies, TAVR appears to be equivalent to SAVR in intermediate as well as high surgical risk patients.
| FINDINGS FROM TAVR VERSUS SAVR STUDIES

| Comparison in intermediate and high risk
In the SURTAVI trial, 1746 patients with intermediate risk (STS Risk of mortality = 4.5%) for surgery were randomized to TAVR (n = 796, Corevalve 84%, EvolutR 16%) and SAVR (n = 864) groups. All-cause death and disabling stroke at the end of 2 years in TAVR was non-inferior to SAVR (13% vs 14%). TAVR group had increased rate of residual aortic regurgitation (AR) at 1 year.
Certain procedure-related adverse outcomes at 30 days were more frequent in SAVR group including atrial fibrillation (AF) (43% vs 13%) and acute kidney injury (4% vs 2%) (Figure1). 1 TAVR is now approved in the United States in intermediate risk patients based on PARTNER IIa trial. 2 The SURTVAI reinforces the findings of PARTNER IIa.
Brenan et al 3 evaluated the safety and effectiveness of TAVR compared to SAVR in intermediate and high-risk propensity in the US
(TVT registry and STS National Database, n = 9464). In this propensitymatched comparison, both groups had similar 1-year mortality, stroke rates, and days alive outside of hospital.
Based on these studies, TAVR appears to be equivalent to SAVR in intermediate as well as high surgical risk patients.
| Valve-in-valve versus redo SAVR
In an observational case-control study, Silaschi et al compared
Valve-in-Valve TAVR (ViV) to redo SAVR in 130 high surgical risk patients (ViV, n = 71; redo-SAVR, n = 59). The decision to perform
ViV or SAVR was made by the heart team. In the ViV cohort, 7 patients were referred for redo-SAVR, but were not eligible due to comorbidity and frailty, severely atherosclerotic aorta or hostile chest (radiation damage). Factors favoring SAVR were anatomical unsuitability for ViV, existence of patient-prosthesis mismatch and low lying left main artery.
Despite advanced age (79 vs 73 years) and higher EuroSCORE (25% vs 17%) in ViV group, 30-day mortality was similar (ViV vs SAVR 4.2 vs 5.1%). Survival at 90 days (94 vs 93%) and 180 days (92 vs 93%) were also similar. "Device success" (VARC2 definition) was lower with ViV (52% vs 92%, P < 0.01), largely due to the presence of residual gradient > 20 mm Hg in 47% of ViV patients. ViV group had lower incidence of stroke (0% vs 3%, P < 0.2), pacemaker implantation (10% vs 25%, P < 0.01), and shorter ICU stay (2 vs 3 days, P < 0.01). 4 While ViV and SAVR are both reasonable for the treatment of failed surgical bioprostheses, customization of care for the individual patient requires integration of several clinical and anatomic characteristics, and should involve a coordinated heart team approach. Swiss TAVI registry (Evolut R, n = 317 and CoreValve, n = 678) Thirty-day outcomes for Evolut R were comparable to CoreValve; moderate to severe aortic regurgitation (9% vs 11%), disabling stroke (2% vs 2%), all-cause mortality (3% vs 3%), and permanent pacemaker implantation (22% vs 23%) Pre-procedural DAPT had higher evidence of bleeding compared to SAPT (37% vs 28%, P = 0.049) and no antiplatelet therapy (37% vs 21%, P = 0.010). No increase in thromboembolic risk in patients without pre-procedural antiplatelet therapy
| NEWER GENERATION VALVE SYSTEMS
In the REPRISE IIE trial the outcomes of fully repositionable and retrievable LOTUS valve were evaluated in 250 high-risk patients.
Thirty-day mortality (4%) and mean valve aortic gradient (12 mmHg) were low compared to predefined performance objective (P < 0.001).
At 1 year mortality was 12% and there was no moderate-severe PVL. 6 The efficacy and safety of CENTERA THV is self-expanding nitinol valve was evaluated in 203 high-risk patients. Thirty-day all-cause mortality was 1%, stroke at 3% and new pacemaker was implanted in only 5% patients, very low despite post dilation in one-third cases.
Moderate PVL was seen in 1%, while no severe PVL was seen.
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At 23 US sites, 241 elderly patients at high surgical risk (STS 7.4%)
were treated with the Evolut R valve, designed to provide a low profile delivery system, conformable annular sealing, and the ability to resheath and reposition during deployment. 8 The majority of patients (90%) were treated by iliofemoral access. Resheathing or recapturing was performed in 23% and more than one valve was required in 1.3%.
The 30-day outcomes included all-cause mortality (2.5%), disabling stroke (3.3%), major vascular complications (7.5%), life-threatening or disabling bleeding (7.1%), and new permanent pacemaker (16%).
Moderate residual paravalvular leak was seen in 5%.
The efficacy and safety of the Evolut R (317) was compared with Medtronic CoreValve (678) from the Swiss TAVI registry analysis.
Evolut R patients had lower STS score (5% vs 7%, P < 0.001) and logistic EuroSCORE (17% vs 20%, P = 0.009), had shorter procedure time and lower use of contrast . Thirty-day clinical outcomes were similar: moderate to severe AR (9% vs 11%), bleeding (5% vs 5%), stroke (2% vs 2%), and all-cause mortality (3% vs 3%). Newer valve systems continue to focus on reduction of PVL and the ability to resheath and reposition the valve.
FIGURE 1 Time-to-event curves for the primary composite end point from SURTAVI trial
Remarkably, these registries demonstrate consistently lower 30-day death than predicted from STS score. annulus area ratio (OR, 0.87; P < 0.001), LVOT calcium volume, and annulus area. With device: annulus ratio of <1, mild/moderate PVL was 53%.
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PVL was assessed in 1661 patients from PARTNER II at 30 days and 1 year. At 30-days 56% had none-trace PVR, 33% had mild, 8%
had mild to moderate, and 4% had at least moderate PVR at 30 days.
At 1 year, 9% of patients had died. Patients with at least moderate PVR had higher 1-year mortality (HR, 2.40; P = 0.005) and the composite of mortality/re-hospitalization (HR, 2.35; P < 0 .001).
Patients with moderate PVR at 30 days had a decrease in PVR severity at 1 year. 12 In 3532 patients in the CoreValve US Pivotal Trials, 782 (22%) received balloon post-dilation. The commonest indication for postdilation was ≥ moderate AR after valve deployment. Post-dilation reduced moderate-severe AR from 58% to 14% at the end of the procedure, but was associated with higher incidence of acute kidney injury (13% vs 10%, P = 0.026).
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Newer valve systems show substantially less PVL than earlier generation valves. Severity of PVL predicts 1-year and long-term mortality, and will continue to serve as the 'bull's eye' for innovations in valve technology. Easily identifiable anatomic features of the annulus and LVOT have been identified as predictors of PVL.
| Conduction disturbances
Naveh et al 14 investigated EKGs during hospitalization and pacemaker interrogation data. Logistic regression showed that pre-existing RBBB (P = 0.01; OR = 18.0) and increased pre-(P = 0.019; OR = 1.14) and post-TAVR PR interval and ΔPR interval (P < 0.001 for both, OR = 1.17)
are independent predictors for long-term pacemaker dependency in
TAVR.
Maeno et al 15 demonstrated that non-coronary cusp devicelanding zone calcium, RBBB, short membranous septum length were independent predictors of new PPMI post 3rd generation SAPIEN 3 in 240 patients. The addition of these factors to three pre-procedural risk factors increased the sensitivity (77-94%) and specificity (87-84%) of the risk model with a higher negative predictive value (96-99%).
Although the risk model will require further validation.
| Subclinical and clinical leaflet thrombosis
Of 890 patients who interpretable CT scans in the RESOLVE or SAVORY registries, 12% had subclinical leaflet thrombosis (SLT) at a median follow up of 3 months after AVR. SLT was less common in SAVR versus TAVR (4% vs 13%, P = 0.001), and among patients receiving anticoagulants versus those receiving dual antiplatelet therapy (DAPT) (4% vs 15%). NOACs were equally as effective as warfarin. SLT resolved in 100% of patients receiving anticoagulants, but persisted in 91% of patients not receiving anticoagulants.
SLT was associated with increased rates of TIAs and all strokes or
TIAs. 16 In a single center study of 642 patients who had undergone TAVR, clinical leaflet thrombosis was seen in 2.8% of patients at a median follow-up of 6 months after TAVR, and was characterized by imaging abnormalities, increased gradients, and elevated BNP levels. It was significantly commoner with balloon-expandable valves and ViV procedures, and effectively treated with anticoagulation. 17 4 | ADJUNCTIVE THERAPIES AND IMAGING IN TAVR
| Thromboembolic prevention strategies in TAVR
In the ARTE Trial, 222 patients were randomized to DAPT (aspirin and clopidogrel) versus aspirin-alone (n = 111 in each group). DAPT patients had more frequent composite of death, MI, stroke, and bleeding (15% vs 7%, P = 0.06) at 3 months (Figure 2A ). Major bleeding at 3 months was higher in DAPT group (11% vs 4%, P = 0.04). There was no significant difference in death, MI, or stroke separately at 3 months ( Figure 2B ). 18 In a single center trial, Ichibori et al 19 demonstrated aspirin alone (n = 78) was more beneficial than DAPT (n = 66) after TAVR. One-year adjusted all-cause death, MI, and stroke were less in aspirin group compared to DAPT (15% vs 30%; P = 0.03) and so were bleeding rates (8% vs 21%, P = 0.02).
Pre-procedural use of DAPT was compared to single and no antiplatelet therapy in 540 patients with TF-TAVR from the OCEAN TAVI registry. DAPT group had higher bleeding events than SAPT (37% vs 28%, P = 0.05) and no antiplatelet therapy (37% vs 21%, P = 0.01). In Median total new lesion volume in all territories was similar in the device versus control groups. Neurocognitive function was similar in control subjects and patients with devices. 22 In a meta-analysis of 16 studies with 1170 patients by Bagur et al, 23 95% had successful delivery of TCEP devices. While there were no differences in stroke or 30-day mortality, the use of TCEP was associated with smaller total or ischemic lesion volume. In subgroup of self-expanding valves, TCEP was associated with significant reduction of new lesions (standardized mean difference, −0.41; P = 0.05).
Based on current randomized trial data, we do not support the routine use of TCEP in patients undergoing TAVR. The data from SENTINEL coupled with the low rate of clinical cerebrovascular events and evolution of valve delivery systems may dampen the enthusiasm for development of newer cerebral protection devices.
| TAVR for pure native AR
In a multicenter registry, early (CoreValve and Sapien XT) and new generation TAVR devices (Evolut R, Sapien 3, JenaValve, Lotus, Direct | 547
Flow, Acurate, Portico, and J-Valve) were compared in 331 patients with pure native AR. Newer devices had higher device success rate (81% vs 61%; P < 0.001), and lower post-procedural AR > moderate (4% vs 19%; P < 0.001). At 1 year, cardiovascular mortality was lower in patients who received newer devices (10% vs 24%, P = 0.008). 24 In an 18-center international registry, Sawaya et al 25 reported the outcomes of TAVR in 146 patients with non-calcific, pure, native AR (n = 78) or failing bio-prosthetic heart valve with pure AR (n = 68). New generation valves were associated with higher device success (85% vs 54%) and better clinical efficacy (75% vs 46%), due to their lower all-cause mortality and ≥ moderate AR. Newer devices also had lower rates of second valve implantation, while older devices had high embolization and migration rates. 25 Given the improvement in outcomes with new generation devices, pure native AR is poised to become an emerging indication for TAVR.
| Mitral regurgitation
Of 11 104 patients from US TVT registry, 31% had moderate MR and 6% severe MR at baseline. One-year mortality was highest in severe MR and lowest in patients with no MR (28% vs 21%, P = 0.0001) and so was re-hospitalization for HF (23% vs 14% Transcaval approach was successful in 99 of 100 patients who were not good candidates for transfemoral, transapical, or direct aortic access. In this approach, aorta is accessed using an electrified caval guidewire that is advanced to a previously placed snare in aorta.
Conventional TAVR is then performed through a transcaval introducer sheath and aorto-caval access site is closed using a nitinol occluder. Inpatient survival was 96%, and 30-day survival was 92%.
Life-threatening bleeding and major vascular complications possibly related to transcaval access were 7% and 13%, respectively. 
| Coronary artery disease
A meta-analysis of 15 studies (n = 8013) was aimed at outcomes in TAVR patients with coronary artery disease. Prevalence of CAD was 49% (range 31-78%). At 30-days no significant difference in mortality was seen in patients with or without CAD. However, CAD did adversely impact mortality at 1-year (OR, 1.2; P = 0.002).
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In a retrospective study, the impact of CAD and its severity based on SYNTAX score (SS), on a composite of death, MI and stroke at 30 days and 1 year was evaluated. Patients with PCI within 6 months of TAVR and prior CABG were categorized based on severity from low SS to high SS. CAD or its severity had no impact on the composite outcome at 30 days or 1 year.
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The optimal management of CAD in patients undergoing TAVR is uncertain. The benefits of revascularization in patients with acute coronary syndromes or stable CAD cannot be extrapolated to patients with severe AS and concomitant CAD. The ongoing ACTIVATION trial and other future large-scale studies will hopefully help to define the need for revascularization in patients undergoing TAVR.
| Anesthesia in TAVR
Using data from the NCDR Registry, Hyman et al 34 studied the use of conscious sedation versus general anesthesia (GA) in 10 997 TAVR patients. Conscious sedation was used in 16% of patients with an increasing trend over time. Although procedural success was similar in both groups, 6% of sedation group had to be converted to GA. The sedation group had shorter hospital stay (6 vs7 days, P < 0.001), lower in-hospital death (2% vs 3%, P = 0.03), 30-day death (3% vs 4%, P = 0.03), and combined 30-day death/stroke rates (4.8% vs 6.4%,
Based on these findings and our personal experience, we believe the trend to use conscious sedation rather than GA for TAVR will continue to gain momentum in the US and abroad.
| Imaging TAVR patients
In 835 to 0% by area) was associated with <8% incidence of PVL. Mismatch was graded severe in 6% with CT compared to 9% with echocardiography. There was no association between 1-year mortality and mismatch with either modality.
36
In our experience, CT-based measurement of LVOT diameter is superior to transthoracic echo. Since the deleterious impact of prosthesis-patient mismatch may not become evident within 1 year, longer-term studies will be helpful. increasing frailty, and was 44% in the frailest patients. Frailty was an independent predictor of late mortality. 37 Afilalo et al 38 evaluated predictive value of seven different frailty scales in 1020 patients undergoing TAVR or SAVR. Frailty ranged from 26% to 68%, depending on the scale used. The Essential Frailty Toolset was the strongest predictor of worsening disability and mortality at 1 year. This score has high inter-observer reliability and can be performed quickly.
The QoL of 184 patients aged 80-93 from POL-TAVI registry was assessed using EQ-5D-3L questionnaire. Severe baseline disability was present in 25%, and decreased to 4% at 30 days after TAVR.
Improvement was seen in all dimensions: including mobility, usual activities, pain, and depression. The change in QoL was regardless of baseline characteristics such as gender, type of anesthesia used, and procedure approach.
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While frailty has consistently predicted worse long-term outcomes, little research has focused on improving frailty measures before TAVR. This is an understudied area imploring future research.
| Blood pressure
Total vascular load includes both steady and pulsatile components.
These parameters can be estimated from non-invasive measurements such as blood pressure and echo-derived stroke volume and cardiac 
